[Possibilities for the clinical use of 5-azacytidine].
The authors report the structure and mechanism of 5-azacytidine action. This drug was first synthesized in the Institute of Organic Chemistry and Biochemistry of Czechoslovak Academy of Sciences (Prague) and used experimentally for leukemia L1210 and leukemic AKR mice and clinically for treatment of acute leukemia in children, in particular.
D000328:Adult; D000818:Animals; D001374:Azacitidine / Q000494:pharmacology / Q000627:therapeutic use*; D001702:Biopharmaceutics; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D051379:Mice; D008806:Mice, Inbred AKR; D008968:Molecular Conformation
D001374:Azacitidine
Vozmozhnosti klinicheskogo primeneniia 5-azatsitidina.